Boehringer Ingelheim, one of the world’s leading research-driven biopharmaceutical companies, has signed a Memorandum of Understanding (MoU) with Aster DM Healthcare, region’s leading integrated healthcare provider, to collaborate on initiatives that strengthen medical education, patient engagement and disease awareness across Cardio-Renal-Metabolic (CRM) diseases in the UAE.
The signing ceremony was attended by representatives from both organizations, including Rahul Kadavakolu, Group Chief Marketing Officer, Aster DM Healthcare, representing Aster DM Healthcare, and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE, and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE, representing Boehringer Ingelheim.
The strategic collaboration reflects a shared commitment to improving patient outcomes through education, prevention and innovation. By combining Aster DM Healthcare’s integrated healthcare ecosystem with Boehringer Ingelheim’s expertise in Cardio-Renal-Metabolic diseases, the partnership aims to enhance clinical knowledge, empower patients, and support earlier intervention through awareness and screening initiatives.
Dr. Malathi Arshanapalai, Group Chief Medical Officer and Group Chief Quality Officer – Aster DM Healthcare, said:
“At Aster, we believe that meaningful partnerships are instrumental in advancing healthcare. Our collaboration with Boehringer Ingelheim reflects our shared commitment to empowering healthcare professionals, improving patient education, and promoting earlier intervention through awareness and screening. By working together, we hope to drive better health outcomes and make a lasting impact on patients living with Cardio-Renal-Metabolic diseases across the region.”
Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE, Boehringer Ingelheim said: “Transforming lives for generations is at the heart of everything we do at Boehringer Ingelheim. As the burden of Cardio-Renal-Metabolic diseases continues to grow, it is becoming increasingly clear that these conditions cannot be addressed in isolation. Improving long-term outcomes requires a more interconnected approach—one that brings together healthcare providers, industry and patients to strengthen prevention, enable earlier intervention and deliver more coordinated care. Our collaboration with Aster DM Healthcare reflects this shared commitment and we hope to contribute to a more resilient healthcare ecosystem and create meaningful impact for patients and communities.”
The collaboration also establishes a framework for future joint initiatives that leverage the strengths of both organizations to address the growing burden of chronic Cardio-Renal-Metabolic diseases. Through educational programs, patient-centered initiatives and preventive healthcare efforts, Boehringer Ingelheim aims to contribute to a more informed healthcare workforce, empowered patients, and healthier communities across the UAE and Jordan.
